HCV envelope protein function is dependent on the peptides preceding the glycoproteins

Biochemical and Biophysical Research Communications

Volumn 378, Issue 1, 2009, Pages 118-122

  Bian, Tao ^a   Zhou, Yongdong ^a   Bi, Shengli ^a   Tan, Wenjie ^a   Wang, Yue ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Envelope protein; Glycosylation; Hepatitis C virus

Indexed keywords

AMINO ACID; ENVELOPE PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2;

AMINO ACID SEQUENCE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GLYCOSYLATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS INFECTIVITY; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CELL LINE; GENOTYPE; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 56949085247     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.11.024     Document Type: Article

References (28)

1. Wang Y., Kato N., Jazag A., Dharel N., Otsuka M., Taniguchi H., Kawabe T., and Omata M. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology 130 (2006) 883-892
2. Liao G., Wang Y., Chang J., Bian T., Tan W., Sun M., Li W., Yang H., Chen J., Zhang X., Bi S., Omata M., and Jiang S. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology 47 (2008) 25-34 Erratum in: Hepatology 47 (2008) 2149
3. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., and Houghton M. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov. 6 (2007) 991-1000 Review. Erratum in: Nat. Rev Drug Discov. 7 (2008) 102. Nat. Rev. Drug Discov. 7 (2008) 458
4. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 (2005) 961-966 Review
5. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements vol. 19, No. 3, June 10-12, 2002.
6. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
7. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 (2004) 5-19
8. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345 (2001) 41-52
9. Goffard A., and Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85 (2003) 295-301
10. Op De Beeck A., Voisset C., Bartosch B., Ciczora Y., Cocquerel L., Keck Z., Foung S., Cosset F.L., and Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78 (2004) 2994-3002
11. Flint M., Logvinoff C., Rice C.M., and McKeating J.A. Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J. Virol. 78 (2004) 6875-6882
12. Lavie M., Goffard A., and Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr. Issues Mol. Biol. 9 (2007) 71-86
13. Voisset C., and Dubuisson J. Functional hepatitis C virus envelope glycoproteins. Biol. Cell. 96 (2004) 413-420
14. Helle F., and Dubuisson J. Hepatitis C virus entry into host cells. Cell. Mol. Life Sci. 65 (2008) 100-112
15. Leroux-Roels G., Depla E., Hulstaert F., Tobback L., Dincq S., Desmet J., Desombere I., and Maertens G. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22 (2004) 3080-3086
16. Yi M., Kaneko S., Yu D.Y., and Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol. 71 (1997) 5997-6002
17. Heile J.M., Fong Y.L., Rosa D., Berger K., Saletti G., Campagnoli S., Bensi G., Capo S., Coates S., Crawford K., Dong C., Wininger M., Baker G., Cousens L., Chien D., Ng P., Archangel P., Grandi G., Houghton M., and Abrignani S. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J. Virol. 74 (2000) 6885-6892
18. Bartosch B., Dubuisson J., and Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197 (2003) 633-642
19. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., and McKeating J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 100 (2003) 7271-7276
20. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F., Verma I., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
21. Miyoshi H., Blomer U., Takahashi M., Gage F., and Verma I. Development of a self-inactivating lentivirus vector. J. Virol. 72 (1998) 8150-8157
22. Cocquerel L., Duvet S., Meunier J.C., Pillez A., Cacan R., Wychowski C., and Dubuisson J. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J. Virol. 73 (1999) 2641-2649
23. Cocquerel L., Op de Beeck A., Lambot M., Roussel J., Delgrange D., Pillez A., Wychowski C., Penin F., and Dubuisson J. Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. EMBO J. 21 (2002) 2893-2902
24. Cocquerel L., Meunier J.C., Pillez A., Wychowski C., and Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J. Virol. 72 (1998) 2183-2191
25. Ciczora Y., Callens N., Penin F., Pécheur E.I., and Dubuisson J. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J. Virol. 81 (2007) 2372-2381
26. Dubuisson J., Duvet S., Meunier J.C., Op De Beeck A., Cacan R., Wychowski C., and Cocquerel L. Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein. J. Biol. Chem. 275 (2000) 30605-30609
27. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 5 (2007) 583-597 Review
28. Tan S.L., Pause A., Shi Y., and Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov. 1 (2002) 867-881